Renal cell carcinoma (RCC) is resistant to chemotherapy, and this resistance is mirrored by a high apoptosis resistance of many RCC lines in vitro. Here, we report the loss of the pro-apoptotic BH3-only protein Bim in a large part of clinical RCC cases and provide evidence for a functional relevance of this loss. Immunohistochemistry of clear cell renal cell carcinoma cases and corresponding normal kidney showed strong Bim reactivity in renal tubules of all cases but loss of Bim in 35 of 45 RCC samples. Out of nine RCC cell lines investigated, six showed strongly diminished or undetectable levels of Bim protein by western blotting. Four RCC lines of varying apoptosis sensitivity were analysed further. Bcl-2, Bcl-x L , Mcl-1, Bax and Bak expression did not correlate with apoptosis sensitivity. All cell lines underwent apoptosis upon forced expression of Bax and Bim, suggesting an upstream difference. In all four lines, adriamycin induced p53 but not its targets Puma or Noxa. However, apoptosis sensitivity correlated with levels of Bim protein. Bim siRNA reduced apoptosis sensitivity in a susceptible cell line. Furthermore, inhibition of histone deacetylation restored Bim expression in cell lines. These data suggest that Bim has a function as a tumor suppressor in RCC.
Introduction
Approximately 2-3% of all malignant tumors in adults develop in the kidney. Of these tumors, 85% are renal cell carcinomas (RCC). The 5-year survival rates of RCC reach 60% in contemporary series. However, 2-year survival is less than 20% in patients with metastatic disease (Mickisch, 2002) . At the time of diagnosis, about 20% of patients have metastatic disease and another 25% present with locally advanced disease. Twenty to forty percent of patients will develop metastases after surgery. This adds up to some 50% of all patients with RCC developing metastases during the course of their disease with the associated poor prognosis (Janzen et al., 2003) .
This clinical resistance is paralleled by a high resistance of many established RCC lines to chemotherapeutic agents in vitro, and this is at least in part the result of a poor apoptotic response. The capacity to die upon certain stimuli through apoptosis is a feature common to all normal cells (Vaux et al., 1994; Hengartner, 2000) . It is assumed that cancer cells have defects in their apoptosis system (Hanahan and Weinberg, 2000; Green and Evan, 2002) . Such resistance to apoptosis may play a role both in the development of cancer and in the resistance to radio-and chemotherapy (Debatin et al., 2002) .
Apoptosis is implemented by an intracellular signal transduction pathway. The morphological changes of apoptosis require the activity of caspase proteases (Salvesen and Dixit, 1997; Earnshaw et al., 1999) , and for most forms of apoptosis the release of cytochrome c is necessary to activate caspases and to implement apoptosis (Green and Reed, 1998; Wang, 2001 ). Resistance to apoptosis may be conveyed by changes in this signal transduction system at various levels.
RCC have been found to be positive for Bcl-2 expression, which has been speculated to contribute to tumor formation , and change in expression of Bcl-2 and Bax have been found to be associated with prognosis in RCC (Kallio et al., 2004) . An earlier report further demonstrated a relative loss of caspase expression in some RCC cell lines (Kolenko et al., 1999) . However, our previous analysis of RCC lines and material directly obtained from patients with RCC failed to confirm this finding and suggested that the events in apoptotic signal transduction that follow the release of cytochrome c are normal in RCC cells (Gerhard et al., 2003) .
This suggests that resistant RCC cells fail to release cytochrome c upon reception of an apoptotic stimulus such as a chemotherapeutic drug. The release of cytochrome c is regulated by the Bcl-2 family of proteins. This family consists of three structurally and functionally distinct groups of proteins. Some proteins (such as Bcl-2 and Bcl-x L ) can inhibit apoptosis in response to most stimuli (Adams and Cory, 2001) . Two proteins (Bax and Bak) have been identified as essential downstream mediators of cytochrome c release (Wei et al., 2001) . A third group is identified by the presence of only one of the so-called Bcl-2 homology (BH) domains, the BH3 domain. These BH3-only proteins act as the most upstream triggers of cytochrome c release known. Current knowledge suggests that an apoptotic stimulus activates one or several BH3-only proteins, which in turn activates Bax and/or Bak to release cytochrome c (Adams and Cory, 2001; Puthalakath and Strasser, 2002; Chen et al., 2005; Willis et al., 2005) . How BH3-only proteins activate Bax/Bak is not entirely clear. Especially two models have been proposed (Labi et al., 2006) but neither is completely compatible with recent experimental data. The 'direct activation' model distinguishes two classes of BH3-only proteins, activators and sensitizers. Activators (initially this group was limited to Bid and Bim but was later extended to include Puma) are suggested directly to bind Bax and cause its activation. Sensitizers, on the other hand, lack this capacity, and their function is limited to binding to prosurvival Bcl-2 proteins, thereby liberating activators and contributing to apoptosis (Kuwana et al., 2002 (Kuwana et al., , 2005 Letai et al., 2002; Kim et al., 2006) . However, a central prediction of this model is that the combined loss of activators blocks all Bax/Bak-dependent apoptosis, but this is not the case (Kim et al., 2006) . The other model, often referred to as the displacement model, assumes that Bax and Bak (direct evidence has been presented for Bak) can auto-activate unless complexed by antiapoptotic Bcl-2 proteins; the function of BH3-only proteins is to inactivate the anti-apoptotic proteins and thus to liberate Bax/Bak . However, the binding capacity of Bak to anti-apoptotic binding partners appears not to be required for its function (Kim et al., 2006) . The question of how BH3-only proteins activate Bax and Bak must therefore at this stage be regarded as not completely answered.
In this study we focus on the apoptotic machinery upstream of cytochrome c release in RCC. Expression of Bim protein was found to be strongly diminished in RCC. Further analysis of the mitochondrial pathway suggests that the loss of Bim is relevant to the resistance to apoptosis in RCC.
Results

Low expression of Bim protein in RCC
We have recently described a loss of expression of the BH3-only protein Nbk/Bik in RCC. However, the functional consequences of this loss were not assessed.
Based on analysis of gene-deficient mice, Bim is the protein with the broadest function within the BH3-only family. Furthermore, Bim has recently been implicated as a tumor suppressor in epithelial cells and in B cells expressing c-myc (Egle et al., 2004; Tan et al., 2005) . We investigated a panel of samples isolated from patients with clear cell renal cell carcinoma (CCRCC) by immunohistochemistry for expression of Bim (a specificity control for the staining procedure is shown in Supplementary Figure 1) . In these patients, the entire kidney had been removed on account of the kidney tumor (except for two renal oncocytomas and one cystic nephroma all tumors were CCRCC). In each case, tumor tissue and tumor-free renal parenchyma were stained in parallel. As shown in Figure 1a , normal kidney showed Bim expression in both proximal and distal tubules. All samples of normal kidney tested showed good staining. However, 35/43 CCRCC (81%) showed weak or undetectable staining for Bim (Figure 1b) , while 8/43 CCRCC (19%) and 3/3 nonmalignant kidney tumors (2 oncocytomas and 1 cystic nephroma) did express Bim in the cytoplasm (Figure 1c and d, and not shown). Primary epithelial cells were further isolated from pairs of tumor and unaffected kidney from seven CCRCC patients as described (Gerhard et al., 2003) and tested by western blotting. As shown in Figure 1e , a clear reduction in Bim expression (tumor compared to unaffected tissue) was observed in five of the seven patients. No reduction was seen in one sample (#3), while very low expression in both unaffected tissue and tumor cells was observed in one instance (#2; although we can retrospectively not exclude the possibility that the macroscopically normal tissue had been infiltrated by the tumor). These data suggest that a loss of Bim expression is a hallmark of CCRCC as it develops from kidney tubular epithelium.
Clinical data were available for 34 of the RCC patients. When stratified according to Bim-staining intensity (undetectable, weak and good staining, Table 1), there was no significant difference in age, grading and T-stage between the groups. However, the presence of metastases showed a trend toward correlation with negative staining for Bim in tumor tissue (Table 1 ; P ¼ 0.2017 for a higher frequency of metastases in Bimnegative cases compared to Bim weak or good cases, Fisher's exact test). Furthermore, b-symptoms (weight loss, fever, night sweat) were somewhat correlated with negative Bim staining in tumor tissue (Table 1 ; P ¼ 0.1069). Although the study had not been designed to test this correlation, the data thus hint at the possibility that the loss of Bim expression is associated with symptoms and with metastases in RCC patients.
Expression of Bim was then assessed in nine RCC cell lines. Six of these showed low or almost undetectable expression, while expression was easily detectable in two lines (84 and MF) and high in one cell line (1M). These results suggest that loss of Bim expression is a frequent event in RCC, both in primary tumors and in RCCderived cell lines. As described earlier (Sturm et al., 2006) , Nbk/Bik expression was not detectable in the cell lines tested (Figure 2 ; data not shown).
The observed reduction of Bim expression may be due to chromosomal deletion or epigenetic regulation such as DNA methylation and histone deacetylation (Bird and Wolffe, 1999) . We tested the latter possibility by treating two Bim-low cell lines (26A and 30) with the methylation inhibitor 5-aza-2 0 -deoxycytidine (5aza2dC) and the broad-spectrum histone deacetylase (HDAC) inhibitor trichostatin A (TSA). As shown in Figure 3 , TSA caused a clear upregulation of Bim in both cell lines, while 5aza2dC had an effect in the line 26A but 
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Renal cell carcinoma and Bim N Zantl et al not the line 30. Some Bim induction was also observed in the Bim-high line 1M (Figure 3a) . A sufficient cell number for this experiment was obtained from three of the primary samples of RCC (patients #1, 6 and 7 in Figure 1 ). Although with varying strength, TSA clearly induced the expression of Bim in all three cases. 5aza2dC was tested in two cases, and there was a visible Bim induction in one case ( Figure 3b ). We further tested the induction of Bim mRNA by TSA in the cell line 26A. TSA induced the expression of all three major splice forms of Bim, with a peak of the levels around 9 h ( Figure 3c ; data not shown). The inclusion of cycloheximide failed to block this induction, suggesting that TSA acted directly through the induction of other factors ( Figure 3c ). Epigenetic regulation therefore appears to be at least one factor that leads to low expression of Bim in RCC cells.
Apoptosis sensitivity in RCC lines correlates with Bim expression but not with expression of other Bcl-2 family members Four RCC lines with varying Bim expression were selected for further analysis (lines shown in the left panel in Figure 2 ). Cell lines were treated with the apoptosis stimuli staurosporine, etoposide, adriamycin or UV irradiation, all of which are known to use the mitochondrial pathway to apoptosis. HeLa cells were included in the experiments as a standard. The observed pattern was as follows: broadly, two cell lines (RCC-26A and -30) were more resistant to all four stimuli than the other two cell lines (RCC-84A and -1M). 26A was clearly the most resistant line, while 1M was the most sensitive line when treated with staurosporine or UV irradiation and similarly sensitive as 84A to treatment with etoposide or adriamycin. The line 30 was highly resistant to staurosporine and UV light but somewhat more sensitive than 26A when treated with etoposide or adriamycin ( Figure 4a ). As shown in Figure 4b , similar differences were found with respect to caspase activation by etoposide-and adriamycin treatment in the two cell lines investigated (26A, resistant, and 1M, sensitive). Sensitivity to apoptosis thus shows correlation with the expression of Bim: 26A and 30, the lines with lowest Bim expression, are very resistant, while the Bim-high line 1M is the line with highest sensitivity.
Alternative explanations for variable apoptosis sensitivity include differential expression of other Bcl-2 family members. Expression analysis of Bcl-2, Bcl-x L , Mcl-1 (anti-apoptotic), Bax and Bak (pro-apoptotic) gave no indication that the differential expression of these proteins was the reason for the different apoptosis sensitivity (Figure 5a ). Although expression differences were observed, no overexpression of anti-apoptotic and no consistent downregulation of pro-apoptotic proteins were seen in the resistant cell lines. For instance, the more resistant line 30 expressed less Bcl-2 and Bcl-x L , but similar amounts of Bax and Bak as the sensitive line 1M. Compared to HeLa cells, the expression levels of Figure 2 Bim expression in renal cell carcinoma (RCC) lines. Cells were extracted and investigated by western blotting. Bim EL expression is detectable to strongly varying levels. Bim L and Bim S were seen when blots were exposed for a long time (see Figure 3) . The cervical carcinoma line HeLa and Mutu I (EBV-positive Burkitt lymphoma) were used as positive controls. and 1M were cultured in the presence or absence of the DNA methylation inhibitor 5aza2dC (3 mM, for 40 h) and/or the broad-spectrum histone deacetylase inhibitor trichostatin A (TSA) (800 nM, 16 h) agents were added at different time points and samples were harvested together (dimethylsulfoxide (DMSO) was a solvent control since TSA was dissolved in DMSO). Cells were harvested and probed for Bim expression as above. One of the three similar experiments is shown. (b) Primary cells isolated from RCC were seeded in plates overnight. Cells were treated as under (a) with the agents indicated and analysed by western blotting. Samples were from the patients #1, 6 and 7 shown in Figure 1 . As loading controls either b-actin (#1) or tubulin (#6 and 7) were used. (c) Induction of Bim mRNA by TSA. Cells from the line KTCTL-26A were cultured in the absence or presence of TSA (800 nM) for the indicated periods. To some aliquots, cycloheximide was added before TSA addition. Total RNA was extracted and subjected to reverse translation and PCR with Bim-specific primers. The positive control was a mixture of plasmids with cDNA of Bim EL , Bim L and Bim S . Primers specific for PBGD (porphobilinogen deaminase) were used to test for cDNA integrity. Similar results were seen in three separate experiments of treatment and RNA isolation.
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Bax were low in all RCC lines, while Bak was relatively highly expressed (Figure 5a ). However, the differences in expression of these proteins between the RCC cell lines do not appear to account for the different apoptosis sensitivities observed.
Besides Bim, other BH3-only proteins could determine apoptosis sensitivity. Nbk/Bik/Blk has been reported to be highly expressed in mouse and human kidney (Daniel et al., 1999; Coultas et al., 2004) . However, low expression of Nbk/Bik in RCC has been reported recently (Sturm et al., 2006) . As expected, we were unable to detect Nbk/Bik expression in any of the RCC lines used (panels in Figure 2 ; data not shown). Puma and Noxa can both participate in the DNAdamage response and might therefore be expected to contribute to sensitivity to UV-and adriamycin-induced apoptosis in RCC. Both are target genes of p53 and are upregulated through p53 (Oda et al., 2000; Han et al., 2001; Nakano and Vousden, 2001 ). Although most RCC lines contain intact p53 and respond to DNA damage with p53 upregulation, p53 has been found to be unable to upregulate p53-dependent reporters or its target gene p21 (Gurova et al., 2004) . We also found that p53 was already expressed in RCC lines and/or strongly upregulated in the RCC lines upon adriamycin treatment ( Figure 5b ). As predicted from the above study, p53 failed to induce the expression of Puma and Noxa. A low, constitutive expression of Puma was seen in all of these RCC lines, but did not correlate with the apoptosis sensitivity. Adriamycin treatment even led to a further decrease in detectable Puma levels (Figure 5b) . Noxa was not detectable in these cell lines by western blotting, without or with adriamycin treatment (data not shown). These results make it unlikely that Puma or Noxa make a significant contribution to the varying apoptosis sensitivity.
The correlation of Bim expression and apoptosis sensitivity suggested that Bim expression was relevant. This line of argument would, however, be strengthened by the demonstration that active Bim was able to induce apoptosis to a similar degree in apoptosis-resistant and -sensitive cell lines. To analyse Bim sensitivity, Bim S was expressed in the cell lines by transient transfection. Bim S is a constitutively active isoform of Bim that is not subject to post-translational modification and activation; all Bim isoforms are presumed to induce apoptosis by the same mechanism (O'Connor et al., 1998; Puthalakath et al., 1999) . Transfection of Bax was included as an additional marker of mitochondrial sensitivity.
Transfection with Bim or Bax induced cell death in all cell lines to a comparable extent. The cell line most sensitive to external apoptotic stimuli, 1M, even appeared somewhat less sensitive than the others to the direct expression of Bax; the sensitivity of 26A and 30 (resistant to external stimuli) to Bim was similar to that of 1M (sensitive; Figure 6 ; expression levels of the proteins were comparable, based on the level of expression of GFP upon transfection; data not shown). Since Bax was able to cause cell death to a similar extent, there is no greater resistance of mitochondria themselves in apoptosis-resistant lines. The sensitivity toward Bim was not reduced in resistant lines, demonstrating that the endogenous levels of Bax and/or Bak must be sufficient to promote an apoptotic signal, and anti-apoptotic proteins (which would also block Bim) are not responsible for the increased apoptosis resistance. Cell death induction by experimental expression of Puma was further tested in the cell lines most (26A) and least (1M) resistant to external stimuli. Like Bim, Puma is a BH3-only protein with a broad apoptosis inducing activity, which is thought to be due to either its capacity of directly activating Bax (in the direct activation model, see above) or its ability to bind all anti-apoptotic Bcl-2 proteins (according to the displacement model). As shown in Figure 6b , there was also no difference in sensitivity to Puma between the lines 26A and 1M, confirming the hypothesis that 'mitochondrial' resistance is not the reason for the differences in apoptosis resistance between the cell lines. 2 for 24 h), etoposide (50 mM for 24 h) and adriamycin (1 mg/ml for 24 h). Apoptosis was measured by nuclear staining with Hoechst dye and visual scoring. Experiments were performed in triplicate, and results are presented as mean7s.d. of the mean apoptosis values obtained in at least three separate experiments for each stimulus. (b) Caspase activity upon treatment with either etoposide or adriamycin in the cell lines 26A (white bars) and 1M (black bars). Cells were treated as under (a). After the time periods given cell extracts were prepared and the cleavage of the effector caspase substrate Ac-DEVD-AMC was measured (control, untreated after 24 h).
The second set of RCC lines (right panel in Figure 2 ) was tested for Bim sensitivity by infection with an adenovirus driving expression of Bim S . Although sensitivity varied somewhat, all cell lines underwent apoptosis upon adenoviral expression of Bim (Figure 7) , which was accompanied by cytochrome c release and caspase-3 activation (not shown).
These data suggested that the low expression of Bim was a determining factor of apoptosis resistance in RCC. To test this directly, Bim was downregulated by RNAi in the cell line 1M, which expresses high levels of Bim. Transfection with Bim-specific siRNA led to a clear decrease in Bim protein levels (Figure 8a ). 1M cells transfected with siRNA specific for Bim had a slightly lower level of spontaneous apoptosis in culture. They also showed a reduced apoptotic response to treatment with etoposide, and staurosporine and, perhaps to a lesser extent, to adriamycin (Figure 8b ). These data indicate that Bim is important for the apoptotic response to these agents in the cell line 1M and suggest that the low expression of Bim in the resistant cell lines determines their poor sensitivity to apoptotic stimuli.
Discussion
This study shows a reduced expression of Bim in RCC. Experiments with RCC lines suggest that this reduction is significant in determining the sensitivity to apoptosis. As Bim is expressed in normal kidney tubular epithelium but not in many cases of CCRCC, the loss of Bim may also contribute to the development of RCC.
In RCC, the cytosolic response to cytochrome c (that is, caspase activation) appears to be normal (Gerhard et al., 2003) . This suggests that apoptosis resistance is the result of defective cytochrome c release. Overexpression of pro-survival Bcl-2-like proteins or reduced expression of Bax/Bak could account for this, but neither was consistently found in the lines tested. Failure to express Puma and Noxa upon adriamycin treatment may be significant here; this is probably the result of a failure of p53 function due to a dominant-negative inhibitor (Gurova et al., 2004 ), which appears to be regulated in a nuclear factor-kB-dependent manner (Gurova et al., 2005) . Expression of Nbk/Bik is also lost during RCC tumorigenesis (Sturm et al., 2006) . Although mice lacking Nbk/Bik were phenotypically normal (Coultas et al., 2004) , the concomitant loss of Bim caused arrest of spermatogenesis, demonstrating that the two proteins can in some way complement each other (Coultas et al., 2005) . It is possible, therefore, that the loss of expression of Nbk/Bik co-operates with the loss of Bim in apoptosis resistance of RCC. In our previous analysis, Nbk/Bik was undetectable in almost all RCC lines and primary RCC samples tested, and this loss was associated with a loss of heterozytosity (LOH) at the nbk locus and silencing of the gene through methylation (Sturm et al., 2006) . Here, we found loss of Bim expression or expression at low levels in about 80% of cases. The loss of Nbk/Bik therefore appears to be a reduces the sensitivity to apoptotic stimuli. 1M cells were transfected as above with either control siRNA (white bars) or with Bim-specific siRNA (black bars). Forty-eight hours later, cells were treated with etoposide (50 mM for 24 h), adriamycin (1 mg/ml for 24 h) or staurosporine (1 mM for 5 h). Nuclear apoptosis was measured by Hoechst staining and microscopy. Similar results were obtained in three experiments. Results shown in (b) and (c) are from the same transfection.
Renal cell carcinoma and Bim N Zantl et al more common event than the loss of Bim expression and it is conceivable that Nbk/Bik loss prepares the ground for a strong apoptosis inhibition conveyed by the loss of Bim. Intriguingly, the loss of Bim was associated with the presence of metastases as well as with symptoms in RCC patients. Although this study was not designed to arrive at a conclusive answer to this question, this indicates the possibility that the loss of Bim is indeed a relevant feature for the progression of RCC in vivo. Furthermore, no marker is available at present to predict the clinical course of RCC. The speculation is enticing that staining for Bim expression might provide such a marker. Future studies will have to address this question.
Recently, two novel kinase inhibitors have been introduced that lead to a detectable clinical response in RCC patients (Kane et al., 2006; Motzer et al., 2007) . However, only a subset of patients did show this response. Although no data are available what could determine the response (or lack of response), the expression of Bim is a candidate factor that might contribute.
Puma and Noxa have been found to be involved in apoptosis in response to DNA-damaging chemotherapeutic agents. Based on results with knockout cells (lymphocytes and fibroblasts), the apoptotic response to DNA-damaging agents appears to involve p53-dependent upregulation/activation of Puma and, to a lesser degree, of Noxa (Jeffers et al., 2003; Villunger et al., 2003) . However, other mechanisms must be able to compensate at least in part for the loss of functional p53 in tumor cells. For instance, HeLa cells (cervical epithelium derived) express the papillomavirus E6 protein, which causes the degradation of p53. However, HeLa cells readily undergo apoptosis upon treatment with adriamycin (see Figure 4) . As expected from previous results, RCC lines in response to adriamycin upregulated p53 but neither Puma nor Noxa. There is, however, evidence that Bim can also contribute to DNA damage-induced apoptosis. Although resistance to g-irradiation-induced apoptosis is clearly greater in Puma-deficient thymocytes (Villunger et al., 2003) , Bim-deficient thymocytes displayed slightly increased resistance (Bouillet et al., 1999) . Activation of Bim has also been reported in response to UV irradiation in the breast cancer cell line MCF-7 (Puthalakath et al., 1999) . Dependent on cell type, Bim may therefore contribute to a number of apoptotic stimuli and may be able to step in when Puma is lost.
The molecular regulation of Bim activity is not completely understood. Although Bim can be regulated on the level of expression (Dijkers et al., 2000; Putcha et al., 2001; Whitfield et al., 2001) , many healthy cells and tissues express easily detectable levels of Bim (O'Reilly et al., 2000) . In these cells, Bim is probably kept inactive by sequestration to the dynein motor complex on microtubules and activated by its release through an unknown mechanism (Puthalakath et al., 1999) . In primary T cells, Bim was reported to be already localized to mitochondria in the absence of apoptosis, and a drop in Bcl-2 and Bcl-x L levels might in this case be the trigger to induce apoptosis (Zhu et al., 2004) . Because the activation mechanism of Bim is not understood more clearly, it is difficult to say which stimuli might activate Bim.
An HDAC inhibitor increased Bim expression in RCC lines and in the three primary cases of RCC that were tested. The induction could not be blocked by cycloheximide and therefore seems not to depend on the induction of other factors. This suggests that epigenetic regulation can cause Bim downregulation by histone deacetylation in RCC; restoration of Bim expression by inhibition of histone deacetylation may therefore be worth considering therapeutically. Of relevance may also be a recent cytogenetic analysis of familial CCRCC, which revealed LOH of chromosome 2q where bim is located (Phillips et al., 2001) . If this was also the case for non-familial forms, chromosomal loss may also contribute to low Bim expression.
In conclusion, the resistance to chemotherapy in RCC may be connected to a loss of expression of BH3-only proteins. Part of this may be the loss of p53 function, which precludes induction of Puma and Noxa in response to DNA-damaging agents. The loss of Bim during the development of RCC, possibly on the backdrop of a previous loss of Nbk/Bik, may further contribute to therapy resistance and may be one of the factors that contribute to tumor formation.
Materials and methods
Cell culture
The following human cell lines from the tumor bank at the Deutsches Krebsforschungszentrum Heidelberg, Germany, were used for this study: KTCTL-1M, KTCTL-26A, KTCTL-30 (all clear cell (CC) carcinoma) and KTCTL-84 (sarcomatoid carcinoma). HeLa and HeP2 cells were from ATCC. Cells were cultured in complete Click's RPMI supplemented with 5% fetal calf serum (FCS), 5 mM glutamine and antibiotics in plastic culture dishes. RCC-MF, KP and GW cell lines were obtained from CLS, Heidelberg, Germany. Cells were grown in RPMI 1640 supplemented with 10% FCS, 100 U/ml penicillin and 0.1 mg/ml streptomycin (GIBCOInvitrogen, Karlsruhe, Germany).
Apoptosis induction
Cells (2 Â 10 5 /well) were treated with one of the following stimuli: staurosporine (Sigma, Munich, Germany), 1 mM for 5 h; UV irradiation, 1600 J/m 2 for 24 h; etoposide (Sigma), 50 mM for 24 h; and adriamycin, 1 mg/ml for 24 h. Cells were stained with Hoechst dye and nuclei were scored for apoptotic morphology by fluorescence microscopy. For detection of effector caspase activity, cells were extracted in NP-40 lysis buffer (Fischer et al., 2001) , triplicates of aliquots were added to a peptide containing a caspase-3-recognition sequence (Acetyl-Asp-Glu-Val-Asp-7,4-amino methyl coumarin; DEVD-AMC, 10 mM) in assay buffer containing bovine serum albumin and Hepes. Free AMC was measured after 1 h of incubation at 371C and values are presented as arbitrary relative fluorescence units (mean7s.d. of triplicate reactions).
Western blot analysis
Cells were washed and extracted in detergent (1% Triton X-100) containing buffer. Extracts were boiled in Laemmli buffer and run on 12% sodium dodecyl sulfate-polyacrylamide gels, transferred to nitrocellulose and subjected to western blotting with the following antibodies directed against: Bcl-2, Bcl-x L , Mcl-1, Bax, Bik (all from Becton Dickinson, Heidelberg, Germany), Bak, p53 (Oncogene Research, San Diego, CA, USA), Bim, Puma, b-actin (Sigma) and Noxa (Alexis, Lausen, Switzerland). Secondary antibodies were peroxidaselabeled anti-mouse or anti-rabbit antibodies as required. Blots were developed using a luminescence system (Perkin Elmer, Waltham, MA, USA). In some experiments, cells were treated with 800 nM TSA (Sigma) or 5aza2dC(3 mM; Sigma) before harvesting.
Analysis of mitochondrial resistance Cells were in triplicate transfected with a b-galactosidase expression vector plus empty vector or the expression vector for Bim or Bax as described earlier (Fischer et al., 2004) . Twenty-four hours later, cultures were stained for b-galactosidase expression and positive (blue) cells were scored alive or dead.
SiRNA transfection
For transfection of cells with siRNA, 3 Â 10 5 cells were seeded in six-well plates. The next day, when cells had reached a confluence level of approximately 70%, siRNA transfection was performed using Lipofectamine 2000 transfection reagent (Invitrogen) according to the manufacturer's protocol. siRNA duplexes specifically targeting Bim expression and a scrambled duplex control were transfected in parallel experiments. Cells were harvested and assayed for gene knockdown or were used for further experiments 48 h after transfection. siRNA duplexes targeting the following sequences were purchased from MWG-Biotech (Martinsried, Germany): siBim 5 0 -CCA CTATCTCAGTGCAATG-3 0 , scrambled duplex 5 0 -CAGTC GCGTTTGCGACTGG-3 0 . siRNA duplexes were used at a final concentration of 200 nM during transfection.
Reverse transcriptase PCR Total cellular RNA from RCC was extracted using the PeqGOLD Trifast Isolation kit (PeqLab, Erlangen, Germany). Total RNA (2 mg) was mixed with an Oligo (dT) primer and was reverse transcribed to cDNA with SuperScript first-strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. The cDNA products were amplified by PCR (GoTaq DNA Polymerase, Promega, Madison, WI, USA) with primers complementary to the target sequence of human Bim. Porphobilinogen deaminase was amplified as a control of cDNA integrity. Amplification PCR conditions were denaturation at 941C for 4 min; 25 cycles of 941C for 30 s, 551C for 30 s, 721C for 1 min and a final extension (721C for 10 min). PCR products were separated by electrophoresis on 2% agarose gels and visualized under UV light after ethidium bromide staining.
Immunohistochemical analysis
Anti-Bim antiserum was generated by injection of GST-hBim L into rabbits (pre-immune serum was used as a control). For immunohistochemistry, a 1:200 dilution of the anti-Bim antiserum was used in a standardized protocol of the automated Ventata Benchmark system. Antigen retrieval was accomplished by ethylenediaminetetraacetic acid and heat pretreatment, and detection of bound antibody was based on the LSAB-AP method. To detect non-specific binding of secondary reagents, one section was incubated with Tris buffer instead of primary antibody.
Forty-three formalin-fixed paraffin-embedded CCRCC and two renal oncocytic adenomas, which had been acquired in a previous study (15), were analysed. Formalin-fixed paraffinembedded cell blocks of RCC cell lines KTCTL-1M and KTCTL-26A served as positive and negative controls. To minimize inter-assay variation, tumors and tumor-free kidney parenchyme were gathered on tissue microarrays using 1 mm punches (Microarray, Beecherinstruments, Sun Prairie, WI, USA).
Adenoviral overexpression of Bim
The E3 region of Ad5 was replaced by the tetracyclindependent transactivator (tTA) under the control of a cytomegalovirus promoter and a SV40 poly(A) tail as described (Gillissen et al., 2003) . A Bim S cDNA was introduced into the E1 region under control of the Tet-off system to achieve conditional expression in the absence of doxycyclin. The resulting Ad5-Bim S -tTA DNA construct was transfected in HEK293 packaging cells to produce vector stocks. Adenoviral stocks were propagated according to standard procedures. RCC cells were transduced with Ad5-Bim S by incubation for 2 h at a multiplicity of infection of 25 in growth medium without FCS. Expression of Bim S was suppressed by addition of 1 mg/ml doxycyclin to the culture medium (Tet-off condition).
Detection of apoptotic cell death by flow cytometry Apoptosis was determined on the single cell level by flow cytometric measuring the DNA content of individual cells. In brief, cells were fixed on ice in 1% formaldehyde followed by 70% ethanol and subsequent treatment with RNAse. Cells were stained with propidium iodide and cellular DNA content was determined with an FACScan (BD Biosciences, Heidelberg, Germany). Data are given as percentage of hypodiploid (sub-G 1 ) cells.
Abbreviations CCRCC, clear cell renal cell carcinoma; HDAC, histone deacetylase; RCC, renal cell carcinoma; TSA, trichostatin A.
